Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Ishan Roy; Gordon Smilnak; Madelyn Burkart; Elizabeth Hamilton; Katherine Thorp; Sarah Miyata; Shuo Ma; Barbara Pro; Jane Winter; Leo Gordon; Reem Karmali

doi:10.1111/bjh.18054

Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Ishan Roy, Gordon Smilnak, Madelyn Burkart, Elizabeth Hamilton, Katherine Thorp, Sarah Miyata, Shuo Ma, Barbara Pro, Jane Winter, Leo Gordon, Reem Karmali^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.

Original language	English (US)
Pages (from-to)	71-75
Number of pages	5
Journal	British Journal of Haematology
Volume	197
Issue number	1
DOIs	https://doi.org/10.1111/bjh.18054
State	Published - Apr 2022

Funding

We thank Masha Kocherginsky, PhD and Sabah Munir, MS of Quantitative Data Sciences Core (QDSC) at the Robert H. Lurie Comprehensive Cancer Center, for statistical consultation.

Keywords

immunotherapy
metabolism
non-Hodgkin lymphoma
quality of life
risk factors

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.18054

Cite this

Roy, I., Smilnak, G., Burkart, M., Hamilton, E., Thorp, K., Miyata, S., Ma, S., Pro, B., Winter, J., Gordon, L., & Karmali, R. (2022). Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. British Journal of Haematology, 197(1), 71-75. https://doi.org/10.1111/bjh.18054

@article{de21be09f5e84f4a95f74955dc69e7fa,

title = "Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma",

abstract = "Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.",

keywords = "immunotherapy, metabolism, non-Hodgkin lymphoma, quality of life, risk factors",

author = "Ishan Roy and Gordon Smilnak and Madelyn Burkart and Elizabeth Hamilton and Katherine Thorp and Sarah Miyata and Shuo Ma and Barbara Pro and Jane Winter and Leo Gordon and Reem Karmali",

note = "Publisher Copyright: {\textcopyright} 2022 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2022",

month = apr,

doi = "10.1111/bjh.18054",

language = "English (US)",

volume = "197",

pages = "71--75",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

Roy, I, Smilnak, G, Burkart, M, Hamilton, E, Thorp, K, Miyata, S, Ma, S, Pro, B, Winter, J , Gordon, L & Karmali, R 2022, 'Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma', British Journal of Haematology, vol. 197, no. 1, pp. 71-75. https://doi.org/10.1111/bjh.18054

TY - JOUR

T1 - Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

AU - Roy, Ishan

AU - Smilnak, Gordon

AU - Burkart, Madelyn

AU - Hamilton, Elizabeth

AU - Thorp, Katherine

AU - Miyata, Sarah

AU - Ma, Shuo

AU - Pro, Barbara

AU - Winter, Jane

AU - Gordon, Leo

AU - Karmali, Reem

PY - 2022/4

Y1 - 2022/4

N2 - Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.

AB - Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.

KW - immunotherapy

KW - metabolism

KW - non-Hodgkin lymphoma

KW - quality of life

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=85124531566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124531566&partnerID=8YFLogxK

U2 - 10.1111/bjh.18054

DO - 10.1111/bjh.18054

M3 - Article

C2 - 35141891

AN - SCOPUS:85124531566

SN - 0007-1048

VL - 197

SP - 71

EP - 75

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this